Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Research article

The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development

Authors: Kamel Rouissi, Islem Ben Bahria, Karim Bougatef, Raja Marrakchi, Nejla Stambouli, Khouloud Hamdi, Mohamed Cherif, Mohamed Riadh Ben Slama, Mohamed Sfaxi, Fethi Ben Othman, Mohamed Chebil, Amel Benammar Elgaaied, Slah Ouerhani

Published in: BMC Cancer | Issue 1/2011

Login to get access

Abstract

Background

In this work, we have conducted a case-control study in order to assess the effect of tobacco and three genetic polymorphisms in XPC, ERCC2 and ERCC5 genes (rs2228001, rs13181 and rs17655) in bladder cancer development in Tunisia. We have also tried to evaluate whether these variants affect the bladder tumor stage and grade.

Methods

The patients group was constituted of 193 newly diagnosed cases of bladder tumors. The controls group was constituted of non-related healthy subjects. The rs2228001, rs13181 and rs17655 polymorphisms were genotyped using a polymerase chain reaction-restriction fragment length polymorphism technique.

Results

Our data have reported that non smoker and light smoker patients (1-19PY) are protected against bladder cancer development. Moreover, light smokers have less risk for developing advanced tumors stage. When we investigated the effect of genetic polymorphisms in bladder cancer development we have found that ERCC2 and ERCC5 variants were not implicated in the bladder cancer occurrence. However, the mutated homozygous genotype for XPC gene was associated with 2.09-fold increased risk of developing bladder cancer compared to the control carrying the wild genotype (p = 0.03, OR = 2.09, CI 95% 1.09-3.99). Finally, we have found that the XPC, ERCC2 and ERCC5 variants don't affect the tumors stage and grade.

Conclusion

These results suggest that the mutated homozygous genotype for XPC gene was associated with increased risk of developing bladder. However we have found no association between rs2228001, rs13181 and rs17655 polymorphisms and tumors stage and grade.
Literature
1.
Silverman DT, Rothman N, Devesa SS, Syrigos KN, Skinner DG: Bladder cancer: biology, diagnosis, and management. 1999, Oxford University Press, New York
2.
Parkin DM, Whelan S, Ferlay J, Leppo L, Thomas DB: Cancer incidence in five continents. 2002, Lyon: IARC Publication
3.
Zeegers MP, Tan FE, Dorant E, van Den Brandt PA: The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000, 89: 630-639. 10.1002/1097-0142(20000801)89:3<630::AID-CNCR19>3.0.CO;2-Q.CrossRefPubMed
4.
Herr HW: Tumor progression and survival of patients with highgrade, non-invasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol. 2000, 163 (1): 60-62. 10.1016/S0022-5347(05)67972-4.CrossRefPubMed
5.
Mao Z, Bozzella M, Seluanov A, Gorbunova V: DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle. 2008, 7: 2902-2906. 10.4161/cc.7.18.6679.CrossRefPubMedPubMedCentral
6.
Christmann M, Tomicic MT, Roos WP, Kaina B: Mechanisms of human DNA repair: an update. Toxicology. 2003, 193: 3-34. 10.1016/S0300-483X(03)00287-7.CrossRefPubMed
7.
Zasimauskas D, Zekonis G: Effect of smoking on neutrophil oxidative metabolism. Medicina. 2008, 443: 195-200.
8.
9.
Lin J, Swan GE, Shields PG, Benowitz NL, Gu J, Amos CI, et al: Mutagen sensitivity and genetic variants in nucleotide-excision repair pathway: genotype-phenotype correlation. Cancer Epidemiol Biomarkers Prev. 2007, 16: 2065-2071. 10.1158/1055-9965.EPI-07-0318.CrossRefPubMed
10.
Gowda S, Kumaran M, Suma BS, Rao MR: Single nucleotide polymorphism analysis of the nucleotide-excision repair genes XPC, XPA, and XPG in the Indian population. Hum Biol. 2007, 79: 545-562.CrossRefPubMed
11.
Egly JM: The 14th Datta Lecture. TFIIH: from transcription to clinic. FEBS Lett. 2001, 498: 124-128. 10.1016/S0014-5793(01)02458-9.CrossRefPubMed
12.
Chen Z, Yang J, Wang G, Song B, Li J, Xu Z: Attenuated expression of xeroderma pigmentosum group C is associated with critical events in human bladder cancer carcinogenesis and progression. Cancer Res. 2007, 67: 4578-4585. 10.1158/0008-5472.CAN-06-0877.CrossRefPubMed
13.
Shen M, Hung RJ, Brennan P, Malaveille C, Donato F, Placidi D, et al: Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in northern Italy. Cancer Epidemiol Biomarkers Prev. 2003, 12: 1234-1240.PubMed
14.
García-Closas M, Malats N, Real FX, Welch R, Kogevinas M, Chatterjee N, et al: Genetic variation in the nucleotide-excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006, 15: 536-542.CrossRefPubMed
15.
Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, et al: Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004, 25 (5): 729-734. 10.1093/carcin/bgh058.CrossRefPubMed
16.
Gao W, Romkes M, Zhong S, Nukui T, Persad RA, Smith PJ, et al: Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk. Oncol Rep. 2010, 24 (1): 257-262.PubMedPubMedCentral
17.
Li C, Jiang Z, Liu X: XPD Lys(751)Gln and Asp (312)Asn polymorphisms and bladder cancer risk: a meta-analysis. Mol Biol Rep. 2010, 37 (1): 301-309. 10.1007/s11033-009-9693-1.CrossRefPubMed
18.
Sambrook J, Fritsch EF, Maniatis T: Molecular cloning: a laboratory manual. 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2
19.
Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, Davico L, et al: DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer. 2001, 92: 562-567. 10.1002/ijc.1228.CrossRefPubMed
20.
Excoffier L, Laval G, Schneider S: Arlequin (version 3.0): An integrated software package for population genetics data analysis. Evol Bioinform Online. 2005, 1: 47-50.
21.
Feng Z, Hu W, Rom WN, Beland FA, Tang MS: 4-aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene. Carcinogenesis. 2002, 23: 1721-1727. 10.1093/carcin/23.10.1721.CrossRefPubMed
22.
Ouerhani S, Rouissi K, Kourda N, Marrakchi R, Bougatef K, Riadh Ben Slama M, et al: Combined analysis of smoking, TP53, and FGFR3 mutations in Tunisian patients with invasive and superficial high-grade bladder tumors. Cancer Invest. 2009, 27 (10): 998-1007. 10.3109/07357900902849707.CrossRefPubMed
23.
Thompson IM, Peek M, Rodriguez FR: The impact of cigarette smoking on stage, grade and number of recurrences of transitional cell carcinoma of the bladder. J Urol. 1987, 137 (3): 401-403.PubMed
24.
Goode EL, Ulrich CM, Potter JD: Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002, 11: 1513-1530.PubMed
25.
Mechanic LE, Millikan RC, Player J, de Cotret AR, Winkel S, Worley K, et al: Polymorphisms in nucleotide excision repair genes, smoking and breast cancer in African Americans and whites: a population-based case-control study. Carcinogenesis. 2006, 27 (7): 1377-1385. 10.1093/carcin/bgi330.CrossRefPubMed
26.
Agalliu I, Kwon EM, Salinas CA, Koopmeiners JS, Ostrander EA, Stanford JL: Genetic variation in DNA repair genes and prostate cancer risk: results from a population-based study. Cancer Causes Control. 2010, 21 (2): 289-300. 10.1007/s10552-009-9461-5.CrossRefPubMed
27.
de Verdier PJ, Sanyal S, Bermejo JL, Steineck G, Hemminki K, Kumar R: Genotypes, haplotypes and diplotypes of three XPC polymorphisms in urinary-bladder cancer patients. Mutat Res. 2010, 694 (1-2): 39-44. 10.1016/j.mrfmmm.2010.09.003.CrossRefPubMed
28.
Stern MC, Lin J, Figueroa JD, Kelsey KT, Kiltie AE, Yuan JM, et al: Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: findings from the international consortium of bladder cancer. Cancer Res. 2009, 69 (17): 6857-6864. 10.1158/0008-5472.CAN-09-1091.CrossRefPubMedPubMedCentral
29.
Sak SC, Barrett JH, Paul AB, Bishop DT, Kiltie AE: The polyAT, intronic IVS11-6 and Lys939Gln XPC polymorphisms are not associated with transitional cell carcinoma of the bladder. Br J Cancer. 2005, 92 (12): 2262-2265. 10.1038/sj.bjc.6602616.CrossRefPubMedPubMedCentral
30.
Gangwar R, Ahirwar D, Mandhani A, Mittal RD: Influence of XPD and APE1 DNA repair gene polymorphism on bladder cancer susceptibility in north India. Urology. 2009, 73 (3): 675-680. 10.1016/j.urology.2008.09.043.CrossRefPubMed
31.
Coin F, Bergmann E, Tremeau-Bravard A, Egly JM: Mutations in XPB and XPD helicases found in xeroderma pigmentosum patients impair the transcription function of TFIIH. Embo J. 1999, 18: 1357-1366. 10.1093/emboj/18.5.1357.CrossRefPubMedPubMedCentral
32.
Soussi T, Béroud C: Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer. 2001, 1: 233-240. 10.1038/35106009.CrossRefPubMed
33.
Sakano S, Kumar R, Larsson P, Onelöv E, Adolfsson J, Steineck G, et al: A single-nucleotide polymorphism in the XPG gene, and tumour stage, grade, and clinical course in patients with nonmuscle-invasive neoplasms of the urinary bladder. BJU Int. 2006, 97 (4): 847-851. 10.1111/j.1464-410X.2005.05994.x.CrossRefPubMed
Metadata
Title
The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development
Authors
Kamel Rouissi
Islem Ben Bahria
Karim Bougatef
Raja Marrakchi
Nejla Stambouli
Khouloud Hamdi
Mohamed Cherif
Mohamed Riadh Ben Slama
Mohamed Sfaxi
Fethi Ben Othman
Mohamed Chebil
Amel Benammar Elgaaied
Slah Ouerhani
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-101

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue

Study protocol

Protocol for MInimizing the Risk of Metachronous Adenomas of the CoLorectum with Green Tea Extract (MIRACLE): a randomised controlled trial of green tea extract versus placebo for nutriprevention of metachronous colon adenomas in the elderly population

Research article

Prediction of outcome after diagnosis of metachronous contralateral breast cancer

Research article

Expression pattern of class I histone deacetylases in vulvar intraepithelial neoplasia and vulvar cancer: a tissue microarray study

Research article

Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer

Research article

Breast cancer and human papillomavirus infection: No evidence of HPV etiology of breast cancer in Indian women

Research article

The association of APE1 −656T > G and 1349 T > G polymorphisms and cancer risk: a meta-analysis based on 37 case-control studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits